Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications
暂无分享,去创建一个
Brian Godman | Samantha Alvarez-Madrazo | Stephen Campbell | Anna Bucsics | B. Wettermark | L. Gustafsson | S. Campbell | B. Godman | A. Bucsics | Ulrich Schwabe | Corinne Zara | Jurij Fürst | Lars L. Gustafsson | K. Garuolienė | H. Herholz | S. Alvarez-Madrazo | O. Laius | J. Fraeyman | A. Finlayson | I. Bishop | Jurij Fürst | Marija Kalaba | Kamila Malinowska | U. Schwabe | C. Sermet | L. Voncina | M. van Woerkom | Ott Laius | Catherine Sermet | Iain Bishop | Kristina Garuoliene | Harald Herholz | Marija Kalaba | Kamila Malinowska | Menno van Woerkom | Vanda Marković-Peković | C. Zara | Bjorn Wettermark | Jessica Fraeyman | Christian Berg | Alexander E. Finlayson | Jutta Piessnegger | Vera V. Vlahović-Palčevski | Vanda Markovic-Pekovic | Luka Vončina | Jutta Piessnegger | C. Berg | V. Vlahović‐Palčevski | Anna Bucsics
[1] J. Usher-Smith,et al. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on , 2008, International journal of clinical practice.
[2] M. Bennie,et al. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. , 2014, Journal of comparative effectiveness research.
[3] S. Simoens,et al. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? , 2011, Health policy.
[4] S. Simoens,et al. Generic atypical antipsychotic drugs in Belgium: their influence and implications. , 2013, Journal of comparative effectiveness research.
[5] G. D. De Meyer,et al. POTENTIAL IMPACT OF POLICY REGULATION AND GENERIC COMPETITION ON SALES OF CHOLESTEROL LOWERING MEDICATION, ANTIDEPRESSANTS AND ACID BLOCKING AGENTS IN BELGIUM , 2012, Acta clinica Belgica.
[6] L. Gustafsson,et al. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions , 2012, Expert review of pharmacoeconomics & outcomes research.
[7] L. Gustafsson,et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. , 2012, Journal of comparative effectiveness research.
[8] A. Flett,et al. Getting better value from the NHS drug budget , 2010, BMJ : British Medical Journal.
[9] Francisco Cervantes,et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. , 2013, Blood.
[10] B. Wettermark,et al. Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications , 2010, Front. Pharmacol..
[11] M. Petzold,et al. Impact of Delisting ARBs, Apart from Losartan, on ARB Utilisation Patterns in Denmark: Implications for Other Countries , 2013, Applied Health Economics and Health Policy.
[12] M. Bennie,et al. Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach , 2012 .
[13] L. Gustafsson,et al. Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future , 2011, Expert review of pharmacoeconomics & outcomes research.
[14] L. Gustafsson,et al. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland? , 2013, Quality in primary care.
[15] L. Levin,et al. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. , 2012, Health policy.
[16] M. Civaner. Sale strategies of pharmaceutical companies in a "pharmerging" country: the problems will not improve if the gaps remain. , 2012, Health policy.
[17] Thomas Kahan,et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. , 2010, Health policy.
[18] Shu-Hua Tai,et al. A systematic review and meta‐analysis on the therapeutic equivalence of statins , 2010, Journal of clinical pharmacy and therapeutics.
[19] B. Wettermark,et al. Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs , 2012, PharmacoEconomics.
[20] S. Kälvemark Sporrong,et al. Pharmacist-patient communication in Swedish community pharmacies. , 2014, Research in social & administrative pharmacy : RSAP.
[21] B. Wettermark,et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications , 2010, Expert review of pharmacoeconomics & outcomes research.
[22] J. Peláez de Loño. [Generic medicines]. , 1999, Revista de enfermeria.
[23] M. Bennie,et al. What lessons can be learned from the launch of generic clopidogrel , 2012 .
[24] M. Bennie,et al. Essential to increase the use of generics in Europe to maintain comprehensive health care , 2012 .
[25] B. Wettermark,et al. Soft regulations in pharmaceutical policy making , 2009, Applied health economics and health policy.
[26] S. Simoens,et al. PP062—Variable approaches in europe to the availability of generic losartan; implications for the future , 2013 .
[27] S. Simoens,et al. Generic Medicines: Solutions for a Sustainable Drug Market? , 2013, Applied Health Economics and Health Policy.
[28] B. Wettermark,et al. Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe? , 2010, Pharmaceuticals.
[29] A. Haycox,et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs , 2011, Expert review of pharmacoeconomics & outcomes research.
[30] Panos Kanavos,et al. Managed entry agreements for pharmaceuticals: the European experience , 2013 .
[31] F. Granath,et al. Potential savings without compromising the quality of care , 2009, International journal of clinical practice.
[32] B. Godman,et al. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents. , 2013, Health policy.
[33] B. Godman,et al. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium , 2013, Expert review of pharmacoeconomics & outcomes research.
[34] M. Bennie,et al. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland , 2012, Expert review of pharmacoeconomics & outcomes research.
[35] R. Malmström,et al. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries , 2013, International journal of clinical practice.
[36] A. Haycox,et al. Enhancing the rational use of new medicines across European health care systems , 2008, European Journal of Clinical Pharmacology.
[37] A. Haycox,et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs , 2013, Front. Pharmacol..
[38] Marianne Klemp,et al. What principles should govern the use of managed entry agreements? , 2011, International Journal of Technology Assessment in Health Care.
[39] B. Wettermark,et al. Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications , 2013 .
[40] L. Pani,et al. Managed entry agreements , 2014, Orphanet Journal of Rare Diseases.